Skip to main content

Table 9 Efficacy of recent clinical trials with liposomal paclitaxel in mono or combined therapy

From: Nanomedicine review: clinical developments in liposomal applications

ORR (%)m-PFS (months)m-OS (months)
Wang and Zhang (2014)2014IINSCLCLPTX + carboplatin27175 mg/m244.46
Lu et al. (2015)2015IINSCLCLPTX + gemcitabine + carboplatin483 mg/ml IT + 1000 mg/m2 IV day 1 and 8 + 5 AUC IV day 1 Q3W8116.523.2
Ahn et al. (2014)2014IINSCLCGenexol-PM + gemcitabine 230 mg/m2 day 1 + 1000 mg/m2 days 1 and 8 IV Q3W46.5414.8
Hu et al. (2013)a2013IINSCLCLPTX + cis-platin63135 mg PTX/m2 to 175 mg PTX/m2
Ignatiadis et al. (2016)2016IBCEndoTAG-1 + PTX + fluorouracil + epirubicin + cyclophosphamide1522 mg/m2 + 70 mg/m2 IV Q1W + 500 mg/m2 + 100 mg/m2 + 500 mg/m2 Q3W33
Awada et al. (2014)2014IITNBCEndoTAG-1 + PTX5622 mg/m2 + 70 mg/m2 Q1W453.713.0
EndoTAG-15888 mg/m2 Q1W25311.9
Lu et al. (2016)2016IIAGCLPTX + capecitabine34135 mg/m2 IV day 1 + 2000 mg/m2 PO days 1–14 Q3W476.912.5
Xu et al. (2013)2013IIMGCLipusu®30135 mg/m2 IV day 147
Haas et al. (2012)2012IIPCEndoTAG-1 + Gem5011 mg/m2144.18.1
5022 mg/m2144.68.7
544 mg/m2164.49.3
Graziani et al. (2017)2017IIEOCPTX–LCN14175 mg/m23
Strieth et al. (2013)b2013IHNCEndoTAG-151.1 mg PTX/kg
Slingerland et al. (2017)b2013IIACLEP-ETU30175 mg PTX/m2 Q3W
  1. LF liposomal formulation, n number of patients, ORR objective response rate, m-PFS median progression-free survival, m-OS median overall survival, LPTX liposomal paclitaxel, PTX–LCN paclitaxel lipid core nanoparticle, PTX paclitaxel, Gem gemcitabine, LEP-ETU paclitaxel liposomal; Q4W, Q4W, Q3W, Q2W, Q1W, every 4, 3, 2 and 1 weeks, respectively, BC breast cancer, TNBC triple-negative breast cancer, AGC atypical glandular cells, MGC metastatic gastric cancer, PC pancreatic cancer, EOC epithelial ovarian carcinoma, HNC head and neck cancer, AC advance cancer, NSCLC non-small-cell lung carcinoma
  2. aNo results have been proportionated
  3. bOnly the toxicity was mentioned